001     125825
005     20240228140801.0
024 7 _ |a 10.5152/dir.2015.15220
|2 doi
024 7 _ |a pmid:26611258
|2 pmid
024 7 _ |a pmc:PMC4712895
|2 pmc
024 7 _ |a 1305-3612
|2 ISSN
024 7 _ |a 1305-3825
|2 ISSN
037 _ _ |a DKFZ-2017-01949
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Flechsig, Paul
|b 0
245 _ _ |a Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer.
260 _ _ |a Ankara
|c 2015
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1524741254_17079
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Staging of lung cancer is typically performed with fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET/CT); however, false positive PET scans can occur due to inflammatory disease. The CT scan is used for anatomic registration and attenuation correction. Herein, we evaluated x-ray attenuation (XRA) within nodes on CT and correlated this with the presence of malignancy in an orthotopic lung cancer model in rats.1×10⁶ NCI-H460 cells were injected transthoracically in six National Institutes of Health nude rats and six animals served as controls. After two weeks, animals were sacrificed; lymph nodes were extracted and scanned with a micro-CT to determine their XRA prior to histologic analysis.Median CT density in malignant lymph nodes (n=20) was significantly higher than benign lymph nodes (n=12; P = 0.018). Short-axis diameter of metastatic lymph nodes was significantly different than benign nodes (3.4 mm vs. 2.4 mm; P = 0.025). Area under the curve for malignancy was higher for density-based lymph node analysis compared with size measurements (0.87 vs. 0.7).XRA of metastatic mediastinal lymph nodes is significantly higher than benign nodes in this lung cancer model. This suggests that information on nodal density may be useful when used in combination with the results of FDG-PET in determining the likelihood of malignant adenopathy.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Radiopharmaceuticals
|2 NLM Chemicals
650 _ 7 |a Fluorodeoxyglucose F18
|0 0Z5B2CJX4D
|2 NLM Chemicals
700 1 _ |a Choyke, Peter
|b 1
700 1 _ |a Kratochwil, Clemens
|b 2
700 1 _ |a Warth, Arne
|b 3
700 1 _ |a Antoch, Gerald
|b 4
700 1 _ |a Holland-Letz, Tim
|0 P:(DE-He78)457c042884c901eb0a02c18bb1d30103
|b 5
|u dkfz
700 1 _ |a Rath, Daniel
|b 6
700 1 _ |a Eichwald, Viktoria
|0 P:(DE-He78)1062e10961e437a74b9dd7542cd4ba7c
|b 7
|u dkfz
700 1 _ |a Huber, Peter
|0 P:(DE-He78)3291aaac20f3d603d96744c1f0890028
|b 8
|u dkfz
700 1 _ |a Kauczor, Hans-Ulrich
|b 9
700 1 _ |a Haberkorn, Uwe
|0 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558
|b 10
|u dkfz
700 1 _ |a Giesel, Frederik
|0 P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94
|b 11
|e Last author
|u dkfz
773 _ _ |a 10.5152/dir.2015.15220
|g Vol. 22, no. 1, p. 35 - 39
|0 PERI:(DE-600)2184145-7
|n 1
|p 35 - 39
|t Diagnostic and interventional radiology
|v 22
|y 2015
|x 1305-3612
909 C O |o oai:inrepo02.dkfz.de:125825
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)457c042884c901eb0a02c18bb1d30103
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)1062e10961e437a74b9dd7542cd4ba7c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)3291aaac20f3d603d96744c1f0890028
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|2 G:(DE-HGF)POF3-300
|v Imaging and radiooncology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b DIAGN INTERV RADIOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)W240-20160331
|k W240
|l Kleintierbildgebung
|x 1
920 1 _ |0 I:(DE-He78)E055-20160331
|k E055
|l Molekulare Radioonkologie
|x 2
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l KKE Nuklearmedizin
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)W240-20160331
980 _ _ |a I:(DE-He78)E055-20160331
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21